ZNF217 and breast carcinoma: ZNF217 is well studied in cancer.53 It is a known breast cancer oncogene and an expression marker for poor prognosis and metastases development.54 Given this, it would be a natural candidate for further studies of the clinical relevance of regulatory mutations once larger data sets become available.